US Stock Market Move | Biopharmaceutical company Evommune (EVMN.US) debuts on the US stock market with a stock price surge of over 15%.
As of the time of publication, the stock has risen by over 15%, to $18.38.
Evommune (EVMN.US) listed on the US stock market, with the stock rising over 15% to $18.38 as of the time of writing, compared to its IPO price of $16. Evommune is a clinical-stage biopharmaceutical company with a mission to treat "immune-mediated chronic inflammatory diseases" through innovative therapies. These diseases include chronic urticaria, atopic dermatitis, and other conditions related to mast cells/inflammation.
Related Articles
US Stock Market Move | Mexican airline (AERO.US) landed on the US stock market and opened with a rise of more than 2.8%.
US Stock Market Move | BEIGENE (ONC.US) rose more than 3% with third-quarter revenue breaking 10 billion and raising its 2025 performance guidance.
US Stock Market Move | SunocoCorp (SUNC.US) debuts on the US stock market with a lower opening stock price.
US Stock Market Move | Mexican airline (AERO.US) landed on the US stock market and opened with a rise of more than 2.8%.
US Stock Market Move | BEIGENE (ONC.US) rose more than 3% with third-quarter revenue breaking 10 billion and raising its 2025 performance guidance.
US Stock Market Move | SunocoCorp (SUNC.US) debuts on the US stock market with a lower opening stock price.
RECOMMEND
SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025
Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025
National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025
